Expert panelists review patient case studies and discuss key updates in the treatment landscape of advanced HCC from the 2023 ASCO Gastrointestinal Cancers Symposium and beyond.
February 20th 2023
Expert panelists discuss treatment strategies for patients with intermediate stage hepatocellular carcinoma (HCC) that are unsuitable for transarterial chemoembolization (TACE).
Expert oncologists discuss a patient profile in advanced HCC, evaluating a patient treated with durvalumab plus tremelimumab.
Experts review clinical studies evaluating TACE in patients with intermediate stage HCC.
Panelists review the HIMALAYA study, investigating durvalumab plus tremelimumab in patients with advanced HCC.
March 6th 2023
Experts discuss the factors they take into consideration when selecting the appropriate treatment in advanced HCC.
Expert oncologists analyze immunotherapy-based combinations in the frontline setting for patients with hepatocellular carcinoma.
March 13th 2023
A panel of oncologists review a patient profile, evaluating a patient with advanced HCC treated with lenvatinib.
Panelists share real-world evidence involving the use of lenvatinib in advanced HCC.
March 20th 2023
Experts discuss treatment options for patients unsuitable for atezolizumab plus bevacizumab in advanced hepatocellular carcinoma.
Oncologists review a patient profile, evaluating treatment approaches for patients with advanced HCC that have progressed beyond 1L treatment.
March 27th 2023
Expert panelists highlight anti-angiogenic systemic therapies under investigation for advanced HCC in second line and beyond.
In the context of frontline treatment strategies in advanced HCC, expert oncologists review clinical research in systemic immunotherapy approaches.
April 3rd 2023
In this discussion, panelists outline treatment considerations for patients with advanced HCC in the 2L setting and beyond.
Oncologists provide an overview of the treatment management of Child-Pugh B patients with advanced HCC.
April 10th 2023
Closing out this discussion, experts share their final thoughts on advanced HCC treatments and key data presented at the 2023 ASCO Gastrointestinal Cancers Symposium.